HC Wainwright Issues Negative Estimate for CRVS Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Research analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Corvus Pharmaceuticals in a note issued to investors on Monday, August 10th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.23) for the quarter, down from their prior estimate of ($0.17). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.37) EPS and FY2029 earnings at ($0.01) EPS.

A number of other equities analysts have also recently commented on the company. Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. The Goldman Sachs Group began coverage on Corvus Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $40.00 price target for the company. Finally, LADENBURG THALM/SH SH raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.33.

Corvus Pharmaceuticals Price Performance

Shares of CRVS stock opened at $14.73 on Wednesday. The company has a market cap of $1.24 billion, a PE ratio of -24.15 and a beta of 0.87. Corvus Pharmaceuticals has a 1 year low of $4.38 and a 1 year high of $26.95. The stock’s 50 day simple moving average is $13.51 and its two-hundred day simple moving average is $15.28.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03).

Insider Transactions at Corvus Pharmaceuticals

In related news, Director David Scott Moore bought 21,700 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $11.53 per share, with a total value of $250,201.00. Following the completion of the purchase, the director owned 21,700 shares of the company’s stock, valued at $250,201. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 19.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in CRVS. BlackRock Inc. bought a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at about $106,654,000. MPM Bioimpact LLC bought a new position in Corvus Pharmaceuticals during the 4th quarter worth about $21,126,000. Commodore Capital LP purchased a new position in Corvus Pharmaceuticals during the 1st quarter valued at about $33,045,000. State Street Corp increased its position in Corvus Pharmaceuticals by 177.1% during the 4th quarter. State Street Corp now owns 2,788,223 shares of the company’s stock valued at $21,469,000 after purchasing an additional 1,781,904 shares during the period. Finally, Perceptive Advisors LLC raised its holdings in shares of Corvus Pharmaceuticals by 231.1% in the 1st quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock valued at $33,538,000 after purchasing an additional 1,600,000 shares in the last quarter. Institutional investors own 46.64% of the company’s stock.

Key Headlines Impacting Corvus Pharmaceuticals

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior report, with a zero-day short-interest ratio. However, the accompanying “NaN” change indicates the data may be incomplete or unreliable, so it provides little actionable insight for investors.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.83 from $0.66 and cut its 2027 forecast to a loss of $0.80 from $0.63. Quarterly estimates were also reduced, including Q3 2026 to a $0.23 loss from $0.17 and Q1–Q2 2027 to losses of $0.23 and $0.24, respectively. HC Wainwright earnings estimates
• Negative Sentiment: Longer-term projections also deteriorated: FY2028 EPS was cut to a $0.37 loss from $0.25, FY2029 was revised to a $0.01 loss from $0.07 profit, and FY2030 was reduced to $0.67 from $0.74. These changes indicate that expected earnings improvement and potential profitability may be arriving later than previously anticipated.
• Negative Sentiment: The revisions reinforce existing earnings risk: Corvus most recently reported a quarterly loss of $0.19 per share, missing the $0.16-loss consensus estimate. The company remains unprofitable, and analysts currently expect a full-year loss of approximately $0.74 per share.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.